FR23C1029I2 - ANTI-CTLA-4 ANTIBODY COMPOSITIONS - Google Patents

ANTI-CTLA-4 ANTIBODY COMPOSITIONS

Info

Publication number: FR23C1029I2
Authority: FR; France
Prior art keywords: ctla; antibody compositions; antibody; compositions
Prior art date: 2005-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1029C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-08

Filing date

2023-07-28

Publication date

2024-06-14

2023-07-28 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2023-10-06 Publication of FR23C1029I1 publication Critical patent/FR23C1029I1/en

2024-06-14 Application granted granted Critical

2024-06-14 Publication of FR23C1029I2 publication Critical patent/FR23C1029I2/en

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Dermatology (AREA)
Virology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)

FR23C1029C 2005-03-08 2023-07-28 ANTI-CTLA-4 ANTIBODY COMPOSITIONS Active FR23C1029I2 (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US65976605P	2005-03-08	2005-03-08
US72816505P	2005-10-19	2005-10-19
US75271205P	2005-12-20	2005-12-20
US76245606P	2006-01-26	2006-01-26
PCT/US2006/007555 WO2006096491A2 (en)	2005-03-08	2006-03-02	Anti-ctla-4 antibody compositions
EP06736812.6A EP1865986B1 (en)	2005-03-08	2006-03-02	Anti-ctla-4 antibody compositions

Publications (2)

Publication Number	Publication Date
FR23C1029I1 FR23C1029I1 (en)	2023-10-06
FR23C1029I2 true FR23C1029I2 (en)	2024-06-14

Family

ID=36646098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR23C1029C Active FR23C1029I2 (en)	2005-03-08	2023-07-28	ANTI-CTLA-4 ANTIBODY COMPOSITIONS

Country Status (26)

Country	Link
US (5)	US20080248047A1 (en)
EP (6)	EP2311491A1 (en)
JP (7)	JP2006249084A (en)
KR (2)	KR100996801B1 (en)
CN (1)	CN103861102A (en)
AR (4)	AR053026A1 (en)
AU (2)	AU2006220828A1 (en)
BR (2)	BRPI0608815B1 (en)
CA (4)	CA2600434C (en)
CY (2)	CY1121254T1 (en)
DK (2)	DK2620450T3 (en)
ES (2)	ES2707284T3 (en)
FI (1)	FIC20230027I1 (en)
FR (1)	FR23C1029I2 (en)
HU (3)	HUE028410T2 (en)
IL (3)	IL185380A0 (en)
LT (2)	LT2620450T (en)
LU (1)	LUC00312I2 (en)
MX (2)	MX2007010971A (en)
NL (1)	NL301240I2 (en)
NZ (2)	NZ560844A (en)
PL (1)	PL2620450T3 (en)
PT (1)	PT2620450T (en)
SI (2)	SI2620450T1 (en)
TW (4)	TW200642694A (en)
WO (4)	WO2006096490A2 (en)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2949290B2 (en)	1989-07-26	1999-09-13	京セラ株式会社	Manufacturing method of amorphous silicon based semiconductor film
AR045563A1 (en)	2003-09-10	2005-11-02	Warner Lambert Co	ANTIBODIES DIRECTED TO M-CSF
EP1709080B1 (en)	2004-01-09	2011-03-09	Pfizer Inc.	ANTIBODIES TO MAdCAM
KR100996801B1 (en) *	2005-03-08	2010-11-25	파마시아 앤드 업존 캄파니 엘엘씨	Anti-MADCAA Antibody Compositions
AU2006283560B2 (en) *	2005-08-19	2011-12-08	Centocor, Inc.	Proteolysis resistant antibody preparations
CL2007002567A1 (en)	2006-09-08	2008-02-01	Amgen Inc	ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
AR063086A1 (en) *	2006-10-02	2008-12-23	Medarex Inc	HUMAN ANTIBODIES THAT JOIN CXCR4 AND USES OF THE SAME
US20080112953A1 (en) *	2006-10-06	2008-05-15	Amgen Inc.	Stable formulations
AU2012200284B2 (en) *	2006-10-06	2014-03-06	Amgen Inc.	Stable Antibody Formulations
KR100784134B1 (en)	2006-10-09	2007-12-12	주식회사 대웅	Stable Liquid Composition for Stomatitis Containing Epithelial Growth Factor
WO2008051363A2 (en)	2006-10-20	2008-05-02	Amgen Inc.	Stable polypeptide formulations
JP5732196B2 (en) *	2006-11-01	2015-06-10	バイオジェンアイデックエムエーインコーポレイティドＢｉｏｇｅｎＩｄｅｃＩｎｃ．	Method for isolating biopolymers using low pH and divalent cations
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations
UA107557C2 (en) *	2007-07-06	2015-01-26		OFATUMUMAB ANTIBODY COMPOSITION
CN101687038A (en) *	2007-07-10	2010-03-31	霍夫曼-拉罗奇有限公司	Novel formulation
EP2205276A4 (en) *	2007-09-28	2012-08-15	Janssen Biotech Inc	Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
SG10201405835TA (en)	2007-11-12	2014-10-30	U3 Pharma Gmbh	Axl antibodies
PE20091174A1 (en) *	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
MX2010014079A (en) *	2008-06-20	2011-02-22	Novartis Ag	Immunoglobulins with reduced aggregation.
TWI445716B (en) *	2008-09-12	2014-07-21	Rinat Neuroscience Corp	Pcsk9 antagonists
TR201802935T4 (en) *	2008-09-19	2018-03-21	Pfizer	Stable liquid antibody formulation.
PE20110302A1 (en) *	2008-09-19	2011-05-21	Hoffmann La Roche	PHARMACEUTICAL FORMULATION OF AN ANTIBODY AGAINST P-SELECTIN
CA2738243C (en)	2008-10-29	2020-09-29	Wyeth Llc	Formulations of single domain antigen binding molecules
CN102272154A (en)	2008-10-29	2011-12-07	惠氏有限责任公司	Methods for purification of single domain antigen-binding molecules
JP2012510468A (en) *	2008-11-28	2012-05-10	アボット・ラボラトリーズ	Stable antibody composition and method for stabilizing the same
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
TWI526223B (en)	2009-05-11	2016-03-21	Ｕ３製藥有限責任公司	Humanized axl antibodies
CA2765220A1 (en) *	2009-07-14	2011-01-20	Biogen Idec Ma Inc.	Methods for inhibiting yellow color and peroxide formation in a composition
ES2604103T3 (en) *	2009-10-01	2017-03-03	F. Hoffmann-La Roche Ag	Final filtration of a multi-step immunoglobulin preparation
EA201892184A1 (en)	2010-03-01	2019-03-29	БАЙЕР ХЕЛЬСКЕР ЛЛСи	OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR
AR080698A1 (en)	2010-04-01	2012-05-02	Imclone Llc	ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
EP3326645B1 (en)	2010-10-25	2020-03-18	Biogen MA Inc.	Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
HUE044038T2 (en) *	2010-11-05	2019-09-30	Novartis Ag	Methods of treating ankylosing spondylitis using anti-il-17 antibodies
JP5458188B2 (en) *	2011-02-17	2014-04-02	協和発酵キリン株式会社	High concentration formulation of anti-CD40 antibody
LT2704742T (en)	2011-05-02	2017-10-25	Millennium Pharmaceuticals, Inc.	Formulation for anti- 4 7 antibody
AU2012285875B2 (en) *	2011-07-18	2016-11-10	Morphosys Ag	Use of c-Fms antagonists
US20130064811A1 (en) *	2011-09-09	2013-03-14	International Business Machines Corporation	Methods to Enhance Cancer Treatment
EP2809350B1 (en) *	2012-01-30	2018-10-17	Arecor Limited	Stabilized aqueous antibody compositions
US20150150979A1 (en) *	2012-06-21	2015-06-04	Ucb Pharma, S.A.	Pharmaceutical formulation
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
MX2015009901A (en)	2013-02-01	2016-04-06	Santa Maria Biotherapeutics Inc	ADMINISTRATION OF AN ANTIACTIVINE COMPOUND TO A SUBJECT.
WO2014159659A1 (en) *	2013-03-12	2014-10-02	Stein Emily A	Dental composition comprising chelator and base
AU2014229282B2 (en)	2013-03-15	2017-02-02	Glaxosmithkline Intellectual Property (No.2) Limited	Low concentration antibody formulations
CN105121466A (en)	2013-04-12	2015-12-02	莫佛塞斯公司	Antibodies targeting m-csf
CN106170298B (en)	2013-10-16	2024-01-09	前瞻疗法公司	Buffer formulations to improve antibody stability
JP2014062100A (en) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	Antibody formulations
EP2946766B1 (en)	2014-05-23	2016-03-02	Ares Trading S.A.	Liquid pharmaceutical composition
EP3050557A1 (en)	2014-05-23	2016-08-03	Ares Trading S.A.	Liquid pharmaceutical composition
CN105296433B (en) *	2014-08-01	2018-02-09	中山康方生物医药有限公司	A kind of CTLA4 antibody, its medical composition and its use
CA3093383A1 (en)	2014-10-24	2016-04-28	Merck Sharp & Dohme Corp.	Co-agonists of the glucagon and glp-1 receptors
CN104357394B (en) *	2014-10-24	2017-03-22	杭州阿诺生物医药科技股份有限公司	Culture method of autologous peripheral blood lymphocyte DC-CIK (Dendritic Cell- Cytokine-induced Killer)
CN105669867A (en) *	2014-11-21	2016-06-15	上海中信国健药业股份有限公司	Anti-GITR/CTLA-4 bispecific antibody, preparation method and application thereof
AR103173A1 (en)	2014-12-22	2017-04-19	Novarits Ag	PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
CA2916283C (en)	2015-01-09	2024-07-02	Pfizer Inc.	Dosage regimen for madcam antagonists
US10696735B2 (en)	2015-01-21	2020-06-30	Outlook Therapeutics, Inc.	Modulation of charge variants in a monoclonal antibody composition
CN118638229A (en)	2015-01-30	2024-09-13	动量制药公司	FCRN antibodies and methods of use thereof
EP3053572A1 (en) *	2015-02-06	2016-08-10	Ares Trading S.A.	Liquid pharmaceutical composition
JP6247241B2 (en) *	2015-02-27	2017-12-13	ノバルティスアーゲー	Antibody prescription
KR20250004095A (en)	2015-04-17	2025-01-07	브리스톨-마이어스 스큅 컴퍼니	Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2016183469A1 (en) *	2015-05-13	2016-11-17	Robert Kirken	Anti-ctla-4 blockade
SI3303394T1 (en)	2015-05-29	2020-10-30	Agenus Inc.	Anti-CTLA-4 antibodies and methods of their use
AR104847A1 (en) *	2015-06-17	2017-08-16	Lilly Co Eli	FORMULATION OF ANTI-CGRP ANTIBODY
WO2017051273A1 (en) *	2015-09-22	2017-03-30	Pfizer Inc.	Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
CN106620691B (en) *	2015-11-04	2020-08-21	信达生物制药(苏州)有限公司	Recombinant fully human anti-CTLA-4 monoclonal antibody preparation and application thereof
CA3010987A1 (en)	2016-01-08	2017-07-13	Replimune Limited	Oncolytic herpes simplex virus type 1 strain
EP3400023A1 (en) *	2016-01-10	2018-11-14	ModernaTX, Inc.	Therapeutic mrnas encoding anti ctla-4 antibodies
MX2018009341A (en)	2016-02-03	2019-05-15	Oncobiologics Inc	Buffer formulations for enhanced antibody stability.
GB201604124D0 (en) *	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
CN105777858B (en) *	2016-03-22	2019-09-10	东软威特曼生物科技(南京)有限公司	The compound stabilizer and its application method of Multiple Antibodies
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3448428A4 (en) *	2016-04-25	2019-11-27	Medimmune, LLC	COMPOSITIONS COMPRISING ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODY CO-FORMULATION
JP7461741B2 (en)	2016-06-20	2024-04-04	カイマブ・リミテッド	Anti-PD-L1 and IL-2 Cytokines
WO2018035710A1 (en)	2016-08-23	2018-03-01	Akeso Biopharma, Inc.	Anti-ctla4 antibodies
CN107815467B (en)	2016-08-31	2021-03-16	百奥赛图(北京)医药科技股份有限公司	Preparation method and application of humanized gene modified animal model
CN107815468B (en)	2016-08-31	2021-03-16	百奥赛图(北京)医药科技股份有限公司	Preparation method and application of humanized genetically modified animal model
WO2018041121A1 (en)	2016-08-31	2018-03-08	Beijing Biocytogen Co., Ltd	Genetically modified non-human animal with human or chimeric ctla-4
WO2018098352A2 (en)	2016-11-22	2018-05-31	Jun Oishi	Targeting kras induced immune checkpoint expression
CN106432499A (en) *	2016-11-24	2017-02-22	上海美迪西生物医药股份有限公司	Preparation method of CTLA-4 antibody FAB in insect expression system
IL266918B2 (en)	2016-12-07	2024-03-01	Agenus Inc	Anti-CTLA-4 antibodies and methods of using them
GB201700350D0 (en)	2017-01-09	2017-02-22	Replimune Ltd	Altered virus
US11608357B2 (en)	2018-08-28	2023-03-21	Arecor Limited	Stabilized antibody protein solutions
GB201703062D0 (en)	2017-02-24	2017-04-12	Arecor Ltd	Stabilized antibody protein solutions
EP3372242A1 (en)	2017-03-06	2018-09-12	Ares Trading S.A.	Liquid pharmaceutical composition
EP3372241A1 (en)	2017-03-06	2018-09-12	Ares Trading S.A.	Liquid pharmaceutical composition
CN106913869B (en) *	2017-03-17	2020-07-28	信达生物制药(苏州)有限公司	A kind of anti-CTLA-4 monoclonal antibody preparation and its application
WO2018204374A1 (en)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
UA129862C2 (en) *	2017-05-02	2025-08-27	Мерк Шарп Енд Доум Елелсі	COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMOR OR CHRONIC INFECTION
JOP20190260A1 (en)	2017-05-02	2019-10-31	Merck Sharp & Dohme	Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN111010866A (en)	2017-05-24	2020-04-14	潘迪恩治疗公司	Targeted immune tolerance
WO2019006003A1 (en) *	2017-06-27	2019-01-03	The Trustees Of Princeton University	Compositions and methods for enhancing immunotherapy
CR20200076A (en)	2017-07-14	2020-06-10	Pfizer	Antibodies to madcam
HRP20240485T1 (en)	2017-08-24	2024-07-05	Novo Nordisk A/S	Glp-1 compositions and uses thereof
KR102816741B1 (en)	2017-08-31	2025-06-04	다이이찌 산쿄 가부시키가이샤	Method for improving the manufacture of antibody-drug conjugates
ES2991988T3 (en)	2017-10-30	2024-12-05	Takeda Pharmaceuticals Co	Environmentally compatible detergents for the inactivation of lipid-enveloped viruses
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174092B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
JP7420720B2 (en)	2017-12-13	2024-01-23	モメンタファーマシューティカルズインコーポレイテッド	FcRn antibodies and their use
US11324774B2 (en)	2018-01-05	2022-05-10	Augusta University Research Institute, Inc.	Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
IL277095B2 (en) *	2018-03-07	2025-10-01	Pfizer	Anti-pd-1 antibody compositions
MX2021000790A (en) *	2018-07-20	2021-07-21	Momenta Pharmaceuticals Inc	Compositions of fcrn antibodies and methods of use thereof.
JP2021533163A (en) *	2018-08-07	2021-12-02	ザブリガムアンドウィメンズホスピタルインコーポレイテッドThe Brigham and Women’s Hospital, Inc.	Methods and Compositions for Annexin A1-mediated Inhibition of Cardiovascular Calcification
US11819504B2 (en)	2018-08-26	2023-11-21	Attain Health Inc.	Methods and compositions to increase hair growth and/or prevent hair loss
IL291545B1 (en) *	2018-10-31	2025-09-01	Bioatla Llc	Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
KR20210089215A (en)	2018-11-07	2021-07-15	머크 샤프 앤드 돔 코포레이션	Co-Formulation of Anti-LAG3 Antibody and Anti-PD-1 Antibody
US11739146B2 (en)	2019-05-20	2023-08-29	Pandion Operations, Inc.	MAdCAM targeted immunotolerance
BR112021024112A2 (en)	2019-06-04	2022-03-22	Jiangsu Hengrui Medicine Co	Antibody capable of binding to thymic stromal lymphopoietin and its use
BR112022004941A2 (en)	2019-09-20	2022-06-28	Novartis Ag	METHODS TO TREAT AUTOIMMUNE DISEASES WITH THE USE OF INTERLEUKIN-17 (IL-17) ANTAGONISTS
KR20220069043A (en) *	2019-09-23	2022-05-26	머크 샤프 앤드 돔 코포레이션	Methods and compositions comprising an anti-CTLA4 monoclonal antibody with reduced host cell protein and increased polysorbate-80 stability
BR112022007635A2 (en) *	2019-11-13	2022-07-12	Pfizer	AQUEOUS AND STABLE ANTIBODY FORMULATION
CN114793422A (en) *	2019-12-25	2022-07-26	百奥泰生物制药股份有限公司	Anti-CTLA-4 monoclonal antibody and preparation method and application thereof
MX2022009844A (en)	2020-02-18	2022-09-05	Novo Nordisk As	Glp-1 compositions and uses thereof.
US11981715B2 (en)	2020-02-21	2024-05-14	Pandion Operations, Inc.	Tissue targeted immunotolerance with a CD39 effector
EP4153130A1 (en) *	2020-05-19	2023-03-29	F. Hoffmann-La Roche AG	The use of chelators for the prevention of visible particle formation in parenteral protein solutions
WO2022026914A1 (en) *	2020-07-31	2022-02-03	Alamab Therapeutics, Inc.	Anti-connexin antibody formulations
AR123340A1 (en) *	2020-08-26	2022-11-23	Janssen Biotech Inc	STABLE FORMULATIONS COMPRISING A BISECFIC ANTIBODY TO EGFR/c-MET
CA3194602A1 (en) *	2020-10-06	2022-04-14	Abraham Oommen	Method for detection of rna or dna from biological samples
WO2022106976A1 (en)	2020-11-18	2022-05-27	Pfizer Inc.	Stable pharmaceutical formulations of soluble fgfr3 decoys
TWI891945B (en) *	2020-12-03	2025-08-01	大陸商江蘇恒瑞醫藥股份有限公司	Anti-tslp antibody pharmaceutical composition and use thereof
CN112569183B (en) *	2020-12-11	2022-12-09	上海赛金生物医药有限公司	Preparation of anti-CTLA-4 antibody and fusion protein
TW202308689A (en) *	2021-04-21	2023-03-01	美商健生生物科技公司	High concentration bispecific antibody formulations
JP2025536574A (en) *	2022-11-04	2025-11-07	アストラゼネカ・アクチエボラーグ	Anti-CTLA antibody compositions and related methods
JP2025538586A (en)	2022-11-22	2025-11-28	武田薬品工業株式会社	Dosing regimens of MAdCAM-1 antibodies for the treatment of nonalcoholic steatohepatitis - Patent Application 20070122999
WO2024186990A1 (en) *	2023-03-09	2024-09-12	Merck Sharp & Dohme Llc	Formulations comprising actriia protein variants
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4597966A (en) *	1985-01-09	1986-07-01	Ortho Diagnostic Systems, Inc.	Histidine stabilized immunoglobulin and method of preparation
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1319120C (en)	1985-04-01	1993-06-15	John Henry Kenten	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
RU1438240C (en)	1987-04-22	1996-03-20	Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН	Recombinant plasmid dna ptnf 22
US5750172A (en)	1987-06-23	1998-05-12	Pharming B.V.	Transgenic non human mammal milk
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
ATE139258T1 (en)	1990-01-12	1996-06-15	Cell Genesys Inc	GENERATION OF XENOGENE ANTIBODIES
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5217954A (en) *	1990-04-04	1993-06-08	Scios Nova Inc.	Formulations for stabilizing fibroblast growth factor
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
AU664976B2 (en)	1990-08-29	1995-12-14	Gene Pharming Europe Bv	Homologous recombination in mammalian cells
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
AU2515992A (en)	1991-08-20	1993-03-16	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
JPH0595794A (en) *	1991-10-04	1993-04-20	Otsuka Pharmaceut Co Ltd	Human m-csf antibody and determination of human m-csf
GB9122820D0 (en) *	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
JP2942412B2 (en) *	1991-12-26	1999-08-30	鐘紡株式会社	Cosmetics
NZ255101A (en)	1992-07-24	1997-08-22	Cell Genesys Inc	A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5589167A (en) *	1993-02-23	1996-12-31	Genentech, Inc.	Excipient stabilization of polypeptides treated with organic solvents
DK0804070T3 (en)	1993-03-09	2000-08-07	Genzyme Corp	Method for isolating proteins from milk
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US7803904B2 (en) *	1995-09-01	2010-09-28	Millennium Pharmaceuticals, Inc.	Mucosal vascular addressing and uses thereof
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en)	1995-04-21	1999-05-27	Cell Genesys, Inc.	Generation of large genomic DNA deletions
EP0822830B1 (en)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	Human antibodies derived from immunized xenomice
US6267958B1 (en) *	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
US20020081294A1 (en) *	1996-01-23	2002-06-27	Genentech, Inc.	Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5994619A (en)	1996-04-01	1999-11-30	University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus	Production of chimeric bovine or porcine animals using cultured inner cell mass cells
GB9610992D0 (en)	1996-05-24	1996-07-31	Glaxo Group Ltd	Concentrated antibody preparation
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
JP3919235B2 (en) *	1997-06-13	2007-05-23	ジェネンテク，インコーポレイテッド	Antibody preparation
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
WO1999045031A2 (en)	1998-03-03	1999-09-10	Abgenix, Inc.	Cd147 binding molecules as therapeutics
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
US20020142374A1 (en)	1998-08-17	2002-10-03	Michael Gallo	Generation of modified molecules with increased serum half-lives
EE05627B1 (en) *	1998-12-23	2013-02-15	Pfizer Inc.	Human monoclonal antibodies to CTLA-4
SI2112166T1 (en) *	1998-12-23	2019-05-31	Pfizer Inc.	Human monoclonal antibodies to ctla-4
US7605238B2 (en)	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
CN1371416B (en) *	1999-08-24	2012-10-10	梅达里克斯公司	Human CTLA-4 antibody and its application
US6517529B1 (en)	1999-11-24	2003-02-11	Radius International Limited Partnership	Hemodialysis catheter
EP1336410A4 (en) *	2000-08-04	2005-10-12	Chugai Pharmaceutical Co Ltd	Protein injection preparations
DK1314437T3 (en) *	2000-08-11	2014-07-14	Chugai Pharmaceutical Co Ltd	Stabilized antibody-containing preparations
IL149701A0 (en)	2001-05-23	2002-11-10	Pfizer Prod Inc	Use of anti-ctla-4 antibodies
CA2454587C (en) *	2001-07-25	2012-11-13	Protein Design Labs, Inc.	Stable lyophilized pharmaceutical formulation of igg antibodies
IL161677A0 (en) *	2001-11-08	2004-09-27	Protein Design Labs	Stable liquid pharmaceutical formulation of igg antibodies
US7330415B2 (en) *	2001-11-15	2008-02-12	Koninklijke Philips Electronics N. V.	Optical record carrier recording method and recording apparatus
US7452539B2 (en) *	2001-12-19	2008-11-18	Genentech, Inc.	Stabilizing polypeptides which have been exposed to urea
MXPA04007924A (en)	2002-02-14	2005-05-17	Chugai Pharmaceutical Co Ltd	Antibody-containing solution pharmaceuticals.
US7132100B2 (en) *	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
WO2004001007A2 (en) *	2002-06-21	2003-12-31	Idec Pharmaceuticals Corporation	Buffered formulations for concentrating antibodies and methods of use thereof
WO2004007520A2 (en) *	2002-07-12	2004-01-22	Medarex, Inc.	Methods and compositions for preventing oxidative degradation of proteins
CA2505994A1 (en) *	2002-11-15	2004-06-03	Chiron Corporation	Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20040191243A1 (en) *	2002-12-13	2004-09-30	Bei Chen	System and method for stabilizing antibodies with histidine
RU2358763C2 (en) *	2003-02-10	2009-06-20	Элан Фармасьютикалз, Инк.	Immunoglobulin compositions and production procedure
DK2335725T3 (en) *	2003-04-04	2017-01-23	Genentech Inc	Highly concentrated antibody and protein formulations
AR045563A1 (en)	2003-09-10	2005-11-02	Warner Lambert Co	ANTIBODIES DIRECTED TO M-CSF
EP1709080B1 (en) *	2004-01-09	2011-03-09	Pfizer Inc.	ANTIBODIES TO MAdCAM
US20060008415A1 (en) *	2004-06-25	2006-01-12	Protein Design Labs, Inc.	Stable liquid and lyophilized formulation of proteins
JO3000B1 (en) *	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
AU2006208226A1 (en) *	2005-01-24	2006-08-03	Amgen Inc.	Humanized anti-amyloid antibody
JP2006249082A (en) *	2005-03-08	2006-09-21	Pharmacia & Upjohn Co Llc	Anti-m-csf antibody composition having endotoxin in reduced level
KR100996801B1 (en) *	2005-03-08	2010-11-25	파마시아 앤드 업존 캄파니 엘엘씨	Anti-MADCAA Antibody Compositions
CA2613017A1 (en) *	2005-07-08	2007-01-18	Pfizer Limited	Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue

2006
- 2006-03-02 KR KR1020077020428A patent/KR100996801B1/en not_active Expired - Fee Related
- 2006-03-02 AR ARP060100793A patent/AR053026A1/en not_active Application Discontinuation
- 2006-03-02 SI SI200632306T patent/SI2620450T1/en unknown
- 2006-03-02 AU AU2006220828A patent/AU2006220828A1/en not_active Abandoned
- 2006-03-02 JP JP2006056818A patent/JP2006249084A/en active Pending
- 2006-03-02 US US11/817,898 patent/US20080248047A1/en not_active Abandoned
- 2006-03-02 US US11/817,894 patent/US9487581B2/en active Active
- 2006-03-02 MX MX2007010971A patent/MX2007010971A/en active IP Right Grant
- 2006-03-02 LT LTEP13155091.5T patent/LT2620450T/en unknown
- 2006-03-02 CA CA2600434A patent/CA2600434C/en active Active
- 2006-03-02 PL PL13155091T patent/PL2620450T3/en unknown
- 2006-03-02 JP JP2006056870A patent/JP2006249085A/en active Pending
- 2006-03-02 AR ARP060100794A patent/AR053553A1/en not_active Application Discontinuation
- 2006-03-02 SI SI200632037A patent/SI1865986T1/en unknown
- 2006-03-02 WO PCT/US2006/007554 patent/WO2006096490A2/en not_active Ceased
- 2006-03-02 WO PCT/US2006/007461 patent/WO2006096461A2/en not_active Ceased
- 2006-03-02 US US11/817,993 patent/US20090110681A1/en not_active Abandoned
- 2006-03-02 WO PCT/US2006/007551 patent/WO2006096488A2/en not_active Ceased
- 2006-03-02 DK DK13155091.5T patent/DK2620450T3/en active
- 2006-03-02 US US11/815,259 patent/US20090238820A1/en not_active Abandoned
- 2006-03-02 WO PCT/US2006/007555 patent/WO2006096491A2/en not_active Ceased
- 2006-03-02 EP EP10185318A patent/EP2311491A1/en not_active Withdrawn
- 2006-03-02 EP EP06736812.6A patent/EP1865986B1/en active Active
- 2006-03-02 HU HUE06736812A patent/HUE028410T2/en unknown
- 2006-03-02 EP EP06736810A patent/EP1858552A2/en not_active Withdrawn
- 2006-03-02 JP JP2006056701A patent/JP5670004B2/en active Active
- 2006-03-02 AR AR20060100796A patent/AR054233A1/en not_active Application Discontinuation
- 2006-03-02 TW TW095107087A patent/TW200642694A/en unknown
- 2006-03-02 ES ES13155091T patent/ES2707284T3/en active Active
- 2006-03-02 TW TW095107021A patent/TWI365747B/en active
- 2006-03-02 DK DK06736812.6T patent/DK1865986T3/en active
- 2006-03-02 CA CA002600588A patent/CA2600588A1/en not_active Abandoned
- 2006-03-02 BR BRPI0608815-5A patent/BRPI0608815B1/en active IP Right Grant
- 2006-03-02 TW TW095107035A patent/TW200719913A/en unknown
- 2006-03-02 JP JP2006056813A patent/JP2006249083A/en active Pending
- 2006-03-02 EP EP06736811A patent/EP1871806A2/en not_active Withdrawn
- 2006-03-02 EP EP06748276A patent/EP1868646A2/en not_active Withdrawn
- 2006-03-02 AR ARP060100795A patent/AR062247A1/en not_active Application Discontinuation
- 2006-03-02 NZ NZ560844A patent/NZ560844A/en unknown
- 2006-03-02 ES ES06736812.6T patent/ES2569409T3/en active Active
- 2006-03-02 BR BRPI0608855-4A patent/BRPI0608855A2/en not_active IP Right Cessation
- 2006-03-02 HU HUE13155091A patent/HUE041802T2/en unknown
- 2006-03-02 MX MX2007010970A patent/MX2007010970A/en unknown
- 2006-03-02 NZ NZ561137A patent/NZ561137A/en unknown
- 2006-03-02 AU AU2006220829A patent/AU2006220829C1/en active Active
- 2006-03-02 CA CA002600608A patent/CA2600608A1/en not_active Abandoned
- 2006-03-02 PT PT13155091T patent/PT2620450T/en unknown
- 2006-03-02 KR KR1020077020433A patent/KR100989280B1/en active Active
- 2006-03-02 CN CN201410109866.6A patent/CN103861102A/en active Pending
- 2006-03-02 EP EP13155091.5A patent/EP2620450B1/en active Active
- 2006-03-02 CA CA002600836A patent/CA2600836A1/en not_active Abandoned
- 2006-03-03 TW TW095107092A patent/TW200709817A/en unknown
2007
- 2007-08-20 IL IL185380A patent/IL185380A0/en unknown
- 2007-08-23 IL IL185483A patent/IL185483A/en active IP Right Grant
2010
- 2010-09-10 US US12/879,916 patent/US20110027262A1/en not_active Abandoned
2012
- 2012-05-21 JP JP2012115478A patent/JP2012167120A/en active Pending
- 2012-10-31 JP JP2012240979A patent/JP2013032387A/en not_active Withdrawn
2013
- 2013-03-21 IL IL225435A patent/IL225435A0/en unknown
2015
- 2015-03-04 JP JP2015042425A patent/JP6212509B2/en active Active
2019
- 2019-01-11 CY CY20191100026T patent/CY1121254T1/en unknown
2023
- 2023-07-28 FR FR23C1029C patent/FR23C1029I2/en active Active
- 2023-07-28 NL NL301240C patent/NL301240I2/en unknown
- 2023-08-01 LU LU00312C patent/LUC00312I2/en unknown
- 2023-08-02 FI FIC20230027C patent/FIC20230027I1/en unknown
- 2023-08-09 CY CY2023018C patent/CY2023018I2/en unknown
- 2023-08-09 LT LTPA2023522C patent/LTC2620450I2/lt unknown
- 2023-08-17 HU HUS2300026C patent/HUS2300026I1/en unknown

Also Published As

Publication number	Publication date
WO2006096488A3 (en)	2006-11-30
SI1865986T1 (en)	2016-05-31
US20110027262A1 (en)	2011-02-03
AR053026A1 (en)	2007-04-18
CA2600434A1 (en)	2006-09-14
WO2006096461A2 (en)	2006-09-14
IL185380A0 (en)	2008-02-09
DK2620450T3 (en)	2019-02-04
JP2012167120A (en)	2012-09-06
WO2006096490A8 (en)	2007-02-01
MX2007010971A (en)	2007-09-19
TW200709817A (en)	2007-03-16
CA2600434C (en)	2017-09-19
AU2006220829B2 (en)	2011-10-13
TW200700081A (en)	2007-01-01
JP2006249081A (en)	2006-09-21
JP2006249083A (en)	2006-09-21
CY2023018I2 (en)	2024-02-16
EP1871806A2 (en)	2008-01-02
US9487581B2 (en)	2016-11-08
EP1868646A2 (en)	2007-12-26
EP2311491A1 (en)	2011-04-20
KR100989280B1 (en)	2010-10-20
WO2006096490A2 (en)	2006-09-14
WO2006096491A2 (en)	2006-09-14
EP2620450A3 (en)	2014-01-08
MX2007010970A (en)	2007-09-19
HUE041802T2 (en)	2019-05-28
FIC20230027I1 (en)	2023-08-02
JP5670004B2 (en)	2015-02-18
FR23C1029I1 (en)	2023-10-06
WO2006096491A3 (en)	2007-03-29
EP2620450A2 (en)	2013-07-31
IL185483A0 (en)	2008-01-06
CA2600588A1 (en)	2006-09-14
EP1865986B1 (en)	2016-02-17
CA2600608A1 (en)	2006-09-14
WO2006096488A2 (en)	2006-09-14
PL2620450T3 (en)	2019-05-31
LTC2620450I2 (en)	2024-11-11
AU2006220829C1 (en)	2025-01-02
BRPI0608815B1 (en)	2021-10-13
US20090110681A1 (en)	2009-04-30
CN103861102A (en)	2014-06-18
SI2620450T1 (en)	2019-01-31
JP2015110656A (en)	2015-06-18
LTPA2023522I1 (en)	2023-09-11
KR100996801B1 (en)	2010-11-25
NZ560844A (en)	2008-08-29
EP1858552A2 (en)	2007-11-28
BRPI0608815A2 (en)	2010-01-26
LT2620450T (en)	2019-02-11
US20080248047A1 (en)	2008-10-09
TW200719913A (en)	2007-06-01
US20090238820A1 (en)	2009-09-24
KR20070100848A (en)	2007-10-11
AU2006220829A1 (en)	2006-09-14
EP1865986A2 (en)	2007-12-19
LUC00312I2 (en)	2025-02-03
CY2023018I1 (en)	2023-11-15
AR054233A1 (en)	2007-06-13
AU2006220828A1 (en)	2006-09-14
WO2006096490A3 (en)	2006-12-28
BRPI0608855A2 (en)	2010-02-02
HK1125297A1 (en)	2009-08-07
IL185483A (en)	2013-04-30
ES2707284T3 (en)	2019-04-03
JP2006249085A (en)	2006-09-21
ES2569409T3 (en)	2016-05-10
HUS2300026I1 (en)	2023-09-28
WO2006096491A9 (en)	2008-04-03
JP6212509B2 (en)	2017-10-11
NZ561137A (en)	2011-09-30
WO2006096461A3 (en)	2006-12-21
AR053553A1 (en)	2007-05-09
US20090130119A1 (en)	2009-05-21
DK1865986T3 (en)	2016-04-11
PT2620450T (en)	2018-12-17
IL225435A0 (en)	2013-06-27
KR20070100922A (en)	2007-10-12
JP2006249084A (en)	2006-09-21
TWI365747B (en)	2012-06-11
CA2600836A1 (en)	2006-09-14
NL301240I2 (en)	2025-07-31
JP2013032387A (en)	2013-02-14
EP2620450B1 (en)	2018-11-07
HUE028410T2 (en)	2016-12-28
TW200642694A (en)	2006-12-16
CY1121254T1 (en)	2020-05-29
AR062247A1 (en)	2008-10-29
BRPI0608815A8 (en)	2017-03-21

Publication	Publication Date	Title
FR23C1029I2 (en)	2024-06-14	ANTI-CTLA-4 ANTIBODY COMPOSITIONS
CY2021033I1 (en)	2022-03-24	INTERLEUKIN-13 ANTIBODY COMPOSITION
FR21C1040I1 (en)	2021-11-19	ANTI-CD20 ANTIBODY FORMULATIONS
MA29014B1 (en)	2007-11-01	ANTIBODY FORMULATIONS
EP1964852A4 (en)	2010-02-24	ANTI-ILT7 ANTIBODIES
ATE464352T1 (en)	2010-04-15	RHEOLOGY-MODIFIED POLYETHYLENE COMPOSITIONS
DK1771482T3 (en)	2014-10-20	HER2 antibody composition
BRPI0511900A (en)	2008-01-22	pharmaceutical compositions
FR15C0048I2 (en)	2015-11-20	IL-17 ANTAGONIST ANTIBODIES
EP2109625A4 (en)	2011-06-08	USE OF ANTIBODY CONJUGATES
ITMI20041252A1 (en)	2004-09-22	PERFLUOROELASTOMERIC COMPOSITIONS
EP1915177A4 (en)	2011-08-31	ALPHA-SYNUCLEIN ANTIBODIES AND RELATED TECHNIQUES
EP1765396A4 (en)	2008-07-02	ANTIBODY
ZA200707293B (en)	2009-04-29	Anti-CTLA-4 antibody compositions
EP1746141A4 (en)	2010-04-07	COMPOSITION FOR THICKENING
DE602005016978D1 (en)	2009-11-12	Mercury-releasing compositions
DK1612200T3 (en)	2013-09-30	fertilizer Composition
EP1967534A4 (en)	2010-12-15	ADHESIVE COMPOSITION
EP2004231A4 (en)	2013-07-10	CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
EP1854467A4 (en)	2011-11-16	COMPOSITION FOR IMMUNE ACTIVATION
DE602005017191D1 (en)	2009-11-26	ODOR-REDUCED WASHPIECE COMPOSITION
EP1937814A4 (en)	2010-05-05	ANTI-APOPTOTIC PROTEIN ANTIBODIES
ITMI20041447A1 (en)	2004-10-20	PHARMACEUTICAL COMPOSITION INCLUDING GABAPENTINA
ITMI20040943A1 (en)	2004-08-11	PHARMACEUTICAL COMPOSITION CICATRIZZANTE
EP1712564A4 (en)	2007-12-05	MONOCLONAL ANTIBODY ANTI-NC1